Search
Ocular Therapeutix Inc
OCULAdd to Watchlist
9.425USD
-0.215-2.23%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
2.04BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of Ocular Therapeutix Inc is 8.67, ranking 13 out of 157 in the Pharmaceuticals industry. The average price target is 22.50, with a high of 31.00 and a low of 18.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
25.636
Target Price
+185.17%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Ocular Therapeutix Inc
OCUL
12
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Ocular Therapeutix Inc's expected revenue for the next quarter?
Ocular Therapeutix Inc's expected revenue is 13.20M.
What is Ocular Therapeutix Inc's price target?
Analysts forecast that Ocular Therapeutix Inc's price target is USD 22.50, with the highest forecast at USD 31.00 and the lowest forecast at USD 18.00.
How have Ocular Therapeutix IncOCUL's recent earnings per share performed?
The market expectation was USD -0.40, while Ocular Therapeutix IncOCUL's earnings per share (EPS) for the previous quarter was USD -0.29. EPS for the next quarter is expected at USD -0.40.
What is the analyst rating for Ocular Therapeutix Inc?
Based on the ratings of Ocular Therapeutix Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
